BRIEF published on 06/20/2024 at 07:35, 2 years 3 months ago GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates Gene Therapy Operational Update GenSight Biologics Financial Negotiation
PRESS RELEASE published on 06/20/2024 at 07:30, 2 years 3 months ago Inside Information / Other news releases GenSight Biologics renegotiates financial obligations and provides operational updates, with successful capital increases enhancing short-term flexibility Financial Obligations Operational Updates GenSight Biologics Capital Increases Gene Therapies
BRIEF published on 06/04/2024 at 07:35, 2 years 3 months ago GenSight Biologics to Present at Key Medical Conferences in 2024 Gene Therapy GenSight Biologics Medical Conferences 2024 LUMEVOQ® LHON
PRESS RELEASE published on 06/04/2024 at 07:30, 2 years 3 months ago Inside Information / Other news releases GenSight Biologics to present at key medical and stakeholder meetings, including 16th Meeting of the EUNOS. Papers on LUMEVOQ® for LHON to be showcased Gene Therapy GenSight Biologics Medical Conferences LUMEVOQ Retinal Neurodegenerative Diseases
BRIEF published on 06/03/2024 at 07:35, 2 years 3 months ago GenSight Biologics Welcomes William Monteith to the Board of Directors Board Of Directors Nomination GenSight Biologics William Monteith Gene Therapies
BRIEF published on 05/23/2024 at 11:40, 2 years 3 months ago Crossing thresholds for GENSIGHT BIOLOGICS SA Actions Crossing Thresholds GenSight Biologics Armistice Capital Subscription Warrants
BRIEF published on 05/07/2024 at 19:34, 2 years 4 months ago GenSight Biologics Announces Availability of Prospectus for New Shares Listing on Euronext Paris Euronext Paris Capital Increase Gene Therapy Prospectus GenSight Biologics
PRESS RELEASE published on 05/07/2024 at 19:29, 2 years 4 months ago Terms of availability of prospectuses GenSight Biologics announces availability of listing prospectus for new shares on Euronext Paris. The prospectus approved by AMF includes universal registration document, securities note, and summary Euronext Paris New Shares AMF Approval GenSight Biologics Listing Prospectus
Published on 09/21/2026 at 15:45, 4 hours 2 minutes ago Datavault AI and Cutting-Edge Sports Management Announce Dream Bowl XV at AT&T Stadium and Launch First-of-Its-Kind Bowl Combine
Published on 09/21/2026 at 14:20, 5 hours 27 minutes ago Doctor's Choice(R) Clinically-Proven Scrubs Launching on Amazon Canada
Published on 09/21/2026 at 14:05, 5 hours 42 minutes ago Winners of this Year's Semmelweis-Richter International Journalism Award Announced
Published on 09/21/2026 at 14:00, 5 hours 47 minutes ago Dateline Files Motion to Resume Operations at Colosseum
Published on 09/21/2026 at 13:45, 6 hours 2 minutes ago Nine Mile Metals DDH WD-26-11 Intersects 2 High Grade VMS Zones Over 27.6M Including 3.08% CU-EQ Over 10.70M, 3.27% CU-EQ Over 9.30M and 4.30% CU-EQ Over 5.0M
Published on 09/21/2026 at 18:00, 1 hour 47 minutes ago Cham Swiss Properties places bond of CHF 100 million
Published on 09/21/2026 at 17:45, 2 hours 2 minutes ago EQS-Adhoc: Airbus reports share buyback transactions 11-18 September 2026
Published on 09/21/2026 at 17:45, 2 hours 2 minutes ago Charwood Energy continues to grow at a strong pace. H1 revenue up +43% to €5.6m.
Published on 09/21/2026 at 17:00, 2 hours 47 minutes ago Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
Published on 09/21/2026 at 18:19, 1 hour 28 minutes ago Reporting on share buyback transactions carried out between September 14 and September 18, 2026
Published on 09/21/2026 at 18:01, 1 hour 46 minutes ago Partnership agreement signed between Manitou Group and HD Construction Equipment
Published on 09/21/2026 at 17:46, 2 hours 1 minute ago WEB SA - STATUTORY HALF-YEAR RESULTS AS OF 30/06/2026
Published on 09/21/2026 at 07:00, 12 hours 47 minutes ago Peugeot Invest takes a stake in Mérieux NutriSciences
